Portrait of Rhonda

About


Dr. Bohn is a pharmacoepidemiologist with over 25 years of experience in the healthcare sector. She received her MPH from Yale University and ScD in Epidemiology from Harvard University. Rhonda has worked in the private sector for pharmaceutical companies, consulting groups, and health insurers as well as spending ten years in academia where she was an Instructor in Medicine at the Brigham and Women’s Hospital and Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics.

She serves on Advisory Boards and Steering Committees for large-scale and multi-database studies and Medical Society Organizations.

Rhonda has authored over 50 articles published in peer-reviewed journals, is an invited speaker for several organizations and is a reviewer for Pharmacoepidemiology and Drug Safety, the Journal of Managed Care Pharmacy, Drug Safety, Thrombosis and Haemostasis, Pediatrics, and Haemophilia.

She is an active member and Fellow of the International Society for Pharmacoepidemiology (ISPE) and served on its Board from 2014–2016.

Rhonda works independently as well as with a team of epidemiologists, statisticians, research assistants, and analysts. She is able to meet client needs in terms of methodological and technical expertise.

Specialties include: Pharmacoepidemiology, Drug Safety Studies, Health Outcomes Research, Risk Management and Evaluation, Use of Large Administrative and EMR Databases for Epidemiologic Research, Corporate Strategy

Two people shaking hands

Clientele


Dr. Bohn's clientele includes large and small global pharmaceutical and biotechnology companies. Within these companies, she works with Pharmacoepidemiology, Health Economic and Outcomes Research, Medical and Clinical Affairs, and Drug Safety groups. When working with a client, Rhonda may work as an epidemiology team member (supporting one or more products or therapeutic areas) or she may serve as a strategic advisor (e.g. during times of organizational growth). She also works on independent projects requiring epidemiology expertise in conjunction with an assembled multi-disciplinary team.

Rhonda’s value resides in her knowledge base, her ability to provide quality deliverables, her accessibility, and her ability to deliver with quick turnaround.

In addition, Rhonda has strong relationships with academic groups, with whom she provides methodological and therapeutic area expertise on a project-by-project basis. Large and small consulting companies call upon Rhonda to engage her in studies where her expertise is needed.

Not everything that can be counted counts, and not everything that counts can be counted. -Albert Einstein, Physicist

Consulting Services


General
Pharmacoepidemiology

Study design

Protocol design and implementation

Study operation and execution

Report generation

Manuscript preparation

Database expertise including multisite collaborations

Registries

Advisory board member (content and therapeutic area)

Therapeutic Area
Expertise

Rare diseases (hemophilia, cystic fibrosis, ALS, LSDs, others)

Rheumatology

Immunology

Neurology

Oncology

Hematology

Cardiovascular disease

Corporate
Strategy

Advise on integration of epidemiology services

Business planning for epidemiology groups

Establishment of and direction of clinical and Methodology advisory boards

Initiate and participate in business collaborations and strategic partnerships

Drug Safety
and Effectiveness

Safety surveillance/monitoring studies

Comparative effectiveness/ safety studies

Safety endpoint validation studies

Risk evaluation and mitigation studies

Natural History
of Disease

Literature reviews

Disease characterization

Burden of illness (incidence, prevalence)

Database studies



Health Economics and
Outcomes Research

Pharmacoeconomic studies

Compliance and persistence

Healthcare utilization



Testimonials


Latest Publications


Gagne JJ, Rassen JA, Choudry NK, Bohn RL, Patrick AR, Sridhar G, Daniel GW, Liu J, Schneeweiss S. Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. Drug Saf 2014;37(3):151-161.

Patorno E, Glynn RJ, Hernandez-Diaz S, Avorn J, Wahl PM, Bohn RL, Mines D, Liu J, Schneeweiss S. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc 2013;2(4):e000208.

Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, Kramer JM, McMahill-Walraven C, Nakasato C, Spettell CM, Syat BL, Wahl PM, Walker AM, Zhang F, Brown JS, Platt R. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf 2012;21(12):1350-1358.